From: The network sustaining action myoclonus: a MEG-EMG study in patients with EPM1
Patient N, gender | Age (years) | Disease Onset (years) | Disease Duration (years) | Score | Treatment (daily dose in mg) |
---|---|---|---|---|---|
#1, F | 28 | 11 | 17 | 2 | VPA 1200, LEV 1000, TPM 200 |
#2, M | 27 | 16 | 11 | 1 | VPA 1750, LEV 3000 |
#3, M | 43 | 14 | 29 | 1 | VPA 1500, ZNS 200 |
#4, M | 52 | 17 | 35 | 1 | VPA 2400, PB 50 |
#5, F | 23 | 11 | 12 | 2 | VPA 1150, LEV 1750 |
#6, M | 54 | 15 | 39 | 2 | VPA 2500, ZNS 200 |
#7, M | 50 | 16 | 34 | 4 | VPA 1800, CZP 1, TPM 300, ZNS 500 |
#8, M | 60 | 16 | 44 | 3 | VPA 1200, PB 150, CZP 1 |
#9, F | 70 | 14 | 56 | 5 | VPA 1300, LEV 2000, TPM 100, CZP 4 |
#10, F | 26 | 11 | 15 | 3 | VPA 1750, ZNS 300 |